AIM ImmunoTech Inc. — Director's Dealing 2018

Nov 16, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2018-11-14

Reporting Person: PASCALE ADAM (CFO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-11-14	Options to buy Common Stock	$0.22	A	1000	Acquired	2028-11-14	Common Stock (1000)	Direct

Footnotes

F1: This option has been awarded by the Board of Directors.